Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanism of resistance to second-line aumolertinib and exploration of post-resistance treatment
ChiCTR2200055992Phase 4Recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Efficacy evaluation. Started Jan 2022; status: recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200055992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055992.